- PDF Free Download

Similar documents

CHEMOTHERAPY aureus 0.10, Enterococcus faecalis 3.13, Escherichia coli 0.20, Klebsiella pneumoniae, Enterobacter spp., Serratia marcescens 0.78, Prote

日本化学療法学会雑誌第64巻第4号

CHEMOTHERAPY Methicillin-resistant S.aureus(MRSA) coccus epidermidis 105 Streptococcus pyogenes E.faecali senterococcus avium Enterococcus faecium Str

日本化学療法学会雑誌第61巻第6号

epidermidis, Enterococcus faecalis, Enterococcus Klebsiella pneumoniae, Proteus mirabilis, indolepositive Proteus spp., Enterobacter spp., Serratia

VOL. 23 NO. 3 CHEMOTHERAPY 1067 Table 2 Sensitivity of gram positive cocci isolated from various diagnostic materials Table 3 Sensitivity of gram nega

DIC vegetation 1 nonbacterial thrombogenic e

CHEMOTHERAPY JUN Citrobacter freundii 27, Enterobacter aerogenes 26, Enterobacter cloacae 27, Proteus rettgeri 7, Proteus inconstans 20, Proteus

THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 Dec LVFX 100 mg 3 / mg 2 / LVFX PK PD mg mg 1 1 AUC/MIC

CHEMOTHERAPY JUNE 1986

03-b-„FŒ{›xŒ¾-4.02

Fig.1 Chemical structure of BAY o 9867

CHEMOTHERAPY DEC (NFLX), ofloxacin (OFLX), ciprofloxacin (CPFX) Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Enterococcus faecali

VOL.32 S-7 CHEMOTHERAPY Table 1 MIC of standard strains of CTRX Fig. 2 Cumulative curves of MIC S. aureus (26 strains )

Key words: E. coli O 157: H7, fosfomycin, verotoxin, mouse infection

Acecide_ProductsInformation2010PDF.indd

E. coli E. coli é H. influenzae Helicobacter pylori

Staphylococcus epidermidis Streptococcus pneumoniae Staphylococcus epidermidis Streptococcus pneumontae S. epidermidis Table 1. Summary of the organis

CHEMOTHERAPY JUNE 1993 Table 1. Background of patients in pharmacokinetic study

Fig.2. Sensitivity distribution of clinical isolates of S. epidermidis (24 strains, 106 CFU/ml) Staphylococcus aureus Staphylococcus epider- midis Ent

988 CHEMOTHERAPY NOV. 1971

Staphylococcus sp. K.pneumoniae P.mirabilis C.freundii E. cloacae Serratia sp. P. aeruginosa ml, Enterococcus avium >100ƒÊg/ml

ヒビスコール液A カタログ

Clostridium difficile ciprofloxacin, ofloxacin, norfloxacin Bifidobacterium Lactobacillus Lactobacillus Bacteroides fragilis B. fragilis C. difficile

CHEMOTHERAPY Proteus mirabilis GN-79 Escherichia coli No. 35 Proteus vulgaris GN-76 Pseudomonas aeruginosa No. 11 Escherichia coli ML-1410 RGN-823 Kle

THE JAPANESE JOURNAL OF ANTIBIOTICS ( 37 ) methicillin-susceptible Staphylococcus aureus (MSSA) Escherichia coli levof

CHEMOTHERAPY APRIL 1992 Acinetobacter calcoaceticus Staphylococcus aureus, Escherichia coli P. aeruginosa E. eoli, Klebsiella pneumoniae Serratia marc

CHEMOTHERAPY NOV S. aureus, S. epidermidis, E. coli, K. pgeumoniae, E. cloacae, S. marcescens, P. mirabilis, Proteus, P. aeruginosa Inoculum siz

日本化学療法学会雑誌第51巻第4号

2.7 臨床概要

Streptococcus pneumoniae,streptococcus pyogenes,streptococcus agalactiae,neisseria gonorrhoeae,h.influenzae,moraxella subgenus Branhamella catarrharis

CHEMOTHERAPY Fig. 1 Chemical structure of CXM-AX

CHEMOTHERAPY DEC Table 1 Antibacterial spectra of T-1982, CTT, CMZ, CTX, CPZ and CEZ 106 CFU/ml Note: P; Peptococcus, S; Streptococcus, G; Gaffk

CHEMOTHERAPY DEC phvlococcus aureus Staphylococcus Enterococcus faecalis Escherichia Klebsiella pneumoniae Serratia marcescens Pseudomonas cepac

Table 1. Antibacterial spectrum SBT ABPC ABPC CPZ : sulbactamiampicillin : ampicillin : cefoperazone

PCG = Benzylpenicillin ABPC= Ampicillin AMPC= Amoxicillin MPIPC = Oxacillin MCIPC = Cloxacillin SBPC= Sulbenicillin PIPC= Piperacillin

日本消化器外科学会雑誌第24巻第12号

08-g-”O−}„j‹ê-4.02

CHEMOTHERAPY JUNE 1987 Table1 Media used *BHIB, brain heart infusion broth (Difco); /3 -NAD, S -nicotinamidoadeninedinucleotide (Sigma Chemical Co.);

小児感染症分離株における感受性サーベイランス

1272 CHEMOTHERAPY MAR. 1975

VOL. 33 S-5 CHEMO THERAPY Fig. 1 Chemical structure of HAPA-B 1-N-[ (2 S)-3-Amino-2-hydroxypropiony1]-4- O-(6-amino-6 - deoxy-ƒ -D- glucopyranosyl) -6

THE JAPANESE JOURNAL OF ANTIBIOTICS 48-8 Enterococcus avium 5Š, Corynebacterium xerosis 10Š, Corynebacterium pseudodiphtheriticum 10Š, Corynebacterium

2 2 THE JAPANESE JOURNAL OF ANTIBIOTICS 69 1 Feb Neisseria gonorrhoeae ceftriaxone CTRX % 2010 CTRX 20 FQ staphylococci, E. faecium, N.

THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 Dec DNA 2, , % 1.65% 1.17% 90% 9 Escherichia coli -

VOL. 20 NO. 5 CHEMOTHERAPY Methoxy-4-sulfanilamidopyrimidine (OS-3376) Sulfadimethoxine (SDM) Table 1. In vitro antibacterial activities of OS-3

Fig. 1 Chemical structure of DL-8280

THE JAPANESE JOURNAL OF ANTIBIOTICS 68 3 June 2015 Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis % 2 S. pneumon

CHEMOTHERAPY OCT Fig. 1 Chemical structure of CVA-K

日本化学療法学会雑誌第59巻第5号

CHEMOTHERAPY Table 1 Clinical effect of Sultamicillin

CHEMOTHERAPY FEB Table 1. Activity of cefpirome and others against clinical isolates

Hisao Takayasu Department of Urology, Faculty of Medicine, University of Tokyo Masaaki Ohkoshi Department of Urology, Tokai University School of Medic

Key words:fatty acid,plant oil,staphylococcus aureus,skin care, atopic dermatitis

Key words : 7432-S, Oral cephem, Urinary tract infection Fig. 1. Chemical structure of 7432-S.

180 ( 64 ) THE JAPANESE JOURNAL OF ANTIBIOTICS June 2011 A b group A Streptococcus: GAS GAS 10 meta-analysis 1) 2,3) GAS potential pathogens Tab

coccus aureus Corynebacterium sp, Haemophilus parainfluenzae Klebsiella pneumoniae Pseudornonas aeruginosa Pseudomonas sp., Xanthomonas maltophilia, F

CHEMO THE RAPY OCT. 1994

Fig. 1 A: Effects of intramuscular injection of glucagon on the blood glucose levels (changes from basal, ƒ BG) as compared with effects of scopolamin

Feb THE JAPANESE JOURNAL OF ANTIBIOTICS Tebipenem pivoxil 1 1, Meiji Seika 2 Meiji Seika G 3 Meiji Seika Tebipen

Physical and Psychological Effects of Stressors in Female College Students Reizou Mita*1, Konosuke Tomabechi*1, Isao Yamaguchi*1, Naoko Soeno*1, Shuhe

ｽﾗｲﾄﾞﾀｲﾄﾙなし

４月号　学会特集号　１２２２４７／１６）一般演題目次

第65回日本化学療法学会東日本支部総会抄録

pneumoniae 30, C. freundii 32, E. aerogenes 27, E. cloacae 32, P. mirabilis 31, P. vulgaris 34, M. morganii 32, S. marcescens 31, H. influenzae 27, P.

04-c-„FŒ{›xŒ¾-4.01

2108 CHEMOTHERAPY SEPT Table 1 Antimicrobial spectrum Fig. 1

CHEMOTHERAPY Table 1 Urinary excretion of mezlocillin Fig. 4 Urinary excretion of mezlocillin Fig. 3 Blood levels of mezlocillin

VOL. 34 S-2 CHEMOTH8RAPY 913

2 2 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 1 Feb CLSI M100-S17benzylpenicillin PCG MIC 0.05 g/ml S. pneumoniae penicillin-susceptible S. pneumon

日本化学療法学会雑誌第53巻第S-3号

日本消化器外科学会雑誌第29巻第9号

VOL.42 S-1 methicillin-susceptible Staphylococcus aureus (MSSA), Staphylococcus epidermidis, Enterococcus faecalis, Escherichia coli, Klebsiella pneum

THE JAPANESE JOURNAL OF ANTIBIOTICS XXII-4 Aug. viable cell number was counted, the number decreased remarkably, then increasedrapidly number as the c

CHEMOTHERAPY Fig. 1 Body weight changes of pregnant mice treated orally with AM- 715 Day of sestation

日本化学療法学会雑誌第60巻第4号

Aug THE JAPANESE JOURNAL OF ANTIBIOTICS (9) 2007 NTT JA

Transcription:

Helicobacter pylori Helicobacter pylori Helkobacter pylori erythromycin (EM) Mueller Hinton broth (Difco) H. pylori Staphylococcus aureus ATCC 29213 Escherichia coli ATCC25922 amoxicillin (AMPC), clarithromycin azithromycin (CAM), (AZM) ciprofloxacin (CPFX) Helicobacter pylori H. pylori H. pylori amoxicillin (AMPC) clarithromycin (CAM) H. pylori erythromycin (EM), roxithromycin CAM, (RXM), azithromycin (AIM) rokitarnycin (RKM) clavulanic acid/amoxicillin fropenem (FRPM) levofloxacin (LVFX)

K. pneumoniae(105) 2%, 1%, E. cloacae(98) 40%, 0%, S. marcescens(86) 21%, 10%, C. freundii(40) 50%, 0 %, P. aeruginosa(446) 12%, 15%, E. faecalis(211) 0%, E. faecium(72) 82%,E.

Immunochromatography polymerase chain reaction

Protective effect of rhg-csf on Trichosporon gell infection in immunosuppressed bei mice Second Department of Internal Medical University. School of Medical Sciencies, Nagasaki University* OP. Kamberi, E. Yamagata, H. Nagai, A. Hashimoto, Y. Goto, T. Tashiro' and M. Nasu Medicine,Oita The effect of rhg-csf alone and in combination with conventional antifungal therapy on the course of disseminated trichosporonosis in neutropenic mice was investigated. ethods. Cyclophosphamide N plus prednisoloneimmunosuppressed mice were inoculated iv with 6x106 CFU of T.beigellii 239,and divided into groups of 12 mice each to receive rhg-csf or and fungal drug. rhg-csf was given sc once daily at30, 60, or 120ƒÊg/kg for 5 days. Ampho ter icin B (MPH, mg/kg),fluconazole(flcz,10mg/kg) or itracona- 1 zole(icz,20mg/kg) was given alone for 7 days or in combination with 60ƒÊg/kg of rhg-csf.three mice per each group were sacrificed on day 4 for quantitative tissue counts of lung(l) and kidney (K).Nine remaining mice in each group were observed for survival for 21 days postinfection. fesults. rhg-csf was protective at 60 and 120 ggikep<0.05 and P<0.01 vs control). Both doses reduced significantly fungus titers in L(P<0.01 vs control) and K(P<0.01 vs control).rhg-csf + either FLCZ or AMPH prolonged survival and signi ficantly reduced tissue burdens, with the former combination being superior.rhgcsf + ICZ resulted in no significant enhancement of the activity. Conclusiaa The administration of rhg-csf to neu tropenic mice augmented resistance against )7 eigelii infection.the effectiveness of combina- b tion rhg-csf + antifungal drug was depend on antifungal drug used.

1)Hatano K, et a1.: Chemother.(Basel) 40: 1-7, 1994 2)Ford C W, et al.:j.med.microbio1.28: 259-266, 1989

Bilophila wadsworthia Bilophila wadsworthia E. coli 20 S. agalactiae P. anaerobius B. fragilis P. bivia cefditoren (CDTR) Acefdinir (CFDN) A cefteram (CFTM) Acefotiam (CTM) Acefpodoxime

Enterococcus casseliflavus E. casseliflavus TUH327 cassellfavus